FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

			_
Washington.	D.C.	20549	

ton, D.C. 20549	OMB APPROVAL

OWID / WIT	(OV)(L				
OMB Number:	3235-0287				
Estimated average bu	ırden				
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Patel Sanjiv (Last) (First) (Middle)				_	Issuer Name and Ticker or Trading Symbol Relay Therapeutics, Inc. [RLAY] Jate of Earliest Transaction (Month/Day/Year)						(Che	elationship of ck all applica Director Officer ((below)	ble)	ing Person(s) to Issuer 10% Owr Other (sp below)		ner	
C/O RELAY THERAPEUTICS, INC. 399 BINNEY STREET, 2ND FLOOR					12/11/2020							President and CEO					
(Street) CAMBR (City)		1A State)	02139 (Zip)	_	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line) 【 Form file	ual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transc Date (Month/L			ate	2A. Deemed Execution Date, if any (Month/Day/Yea		Transaction Disposed Of (D) Code (Instr.		ies Acquired (A) or Of (D) (Instr. 3, 4 and 5)		5. Amount Securities Beneficiall Owned Fol Reported	y (1	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code V Amount (A) or (D)				r Price	Transaction(s) (Instr. 3 and 4)			'				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		saction Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amou Securities Under Derivative Securi (Instr. 3 and 4)			Underlying Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		cpiration ate	Title	Amount or Number of Shares	(Instr. 4)				
Stock Option (Right to Buy)	\$5.22	12/11/2020		A		753,804 ⁽¹⁾		(1)	03.	3/01/2030	Common Stock	753,804 ⁽¹	\$0.00	753,804 ⁰	(1)	D	

Explanation of Responses:

1. On March 2, 2020, the reporting person was granted an option to purchase 753,804 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 188,451 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 565,353 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date.

Remarks:

/s/ Brian Adams, as Attorney-in-

Fact

12/15/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.